LENZ Therapeutics (LENZ) Shares Outstanding (Weighted Average) (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Shares Outstanding (Weighted Average) data on file, last reported at $31.4 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $31.4 million, up 13.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $31.4 million (up 13.9% YoY), and the FY2025 annual result was $28.8 million, up 35.39% from the prior year.
• Shares Outstanding (Weighted Average) grew to $31.4 million in Q1 2026 per LENZ's latest filing, from $28.8 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $58.1 million in Q4 2022 and troughed at $2.0 million in Q1 2023.
• A 5-year average of $32.2 million and a median of $28.5 million in 2025 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Weighted Average) sank 96.63% in 2023, then jumped 986.27% in 2024.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $58.1 million in 2022, then plunged by 96.63% to $2.0 million in 2023, then jumped by 986.27% to $21.3 million in 2024, then surged by 35.39% to $28.8 million in 2025, then climbed by 8.81% to $31.4 million in 2026.
• Business Quant data shows LENZ's Shares Outstanding (Weighted Average) at $31.4 million in Q1 2026, $28.8 million in Q4 2025, and $28.5 million in Q3 2025.